TriangleDISEASE & TREATMENT SETTING
Recurrent Rhabdoid Tumor
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Recurrent Rhabdoid Tumor
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 6 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
- source wording
- Source null
Study evidence for this setting
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-recurrent-rhabdoid-tumor
- binding id
- ncit-C142849
- source collection
- ncit-concept
- source key
- C142849
- source excerpt
- Source null
- match status
- exact
- match note
- Source null
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice